NRx Pharmaceuticals’ (NRXP) Buy Rating Reaffirmed at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $31.00 price target on the stock.

A number of other analysts also recently issued reports on NRXP. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, March 20th. Ascendiant Capital Markets raised their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.

NRx Pharmaceuticals Trading Down 1.9 %

NASDAQ:NRXP opened at $2.03 on Monday. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The company has a market cap of $34.34 million, a P/E ratio of -0.95 and a beta of 1.22. The company’s 50-day moving average price is $2.57 and its 200-day moving average price is $2.05.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AdvisorShares Investments LLC increased its position in shares of NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after purchasing an additional 180,229 shares during the last quarter. Anson Funds Management LP boosted its stake in NRx Pharmaceuticals by 30.3% during the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after buying an additional 43,135 shares during the period. Millennium Management LLC acquired a new stake in shares of NRx Pharmaceuticals during the fourth quarter valued at about $61,000. Squarepoint Ops LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $56,000. Finally, Townsquare Capital LLC acquired a new position in shares of NRx Pharmaceuticals in the 3rd quarter worth approximately $25,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.